-
Product Insights
B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia) – Drugs In Development, 2023
Global Markets Direct’s, ‘B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia) - Drugs In Development, 2023’, provides an overview of the B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia) pipeline landscape. The report provides comprehensive information on the therapeutics under development for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the...
-
Product Insights
Mast Cell Leukemia – Drugs In Development, 2023
Global Markets Direct’s, ‘Mast Cell Leukemia - Drugs In Development, 2023’, provides an overview of the Mast Cell Leukemia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Mast Cell Leukemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
B-Cell Chronic Lymphocytic Leukemia – Drugs In Development, 2023
Global Markets Direct’s, ‘B-Cell Chronic Lymphocytic Leukemia - Drugs In Development, 2023’, provides an overview of the B-Cell Chronic Lymphocytic Leukemia pipeline landscape. The report provides comprehensive information on the therapeutics under development for B-Cell Chronic Lymphocytic Leukemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Hairy Cell Leukemia – Drugs In Development, 2023
Global Markets Direct’s, ‘Hairy Cell Leukemia - Drugs In Development, 2023’, provides an overview of the Hairy Cell Leukemia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hairy Cell Leukemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Clinical Trials Overview The Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) clinical trial report consists of 3259 trials. The report provides an overview of the Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) clinical trial scenario. The report provides top-line data relating to the clinical trials on Acute Lymphocytic Leukemia. It also includes an overview of trial numbers and their average enrolment in top countries conducted across the globe. Moreover, it offers coverage of...
-
Sector Analysis
Chronic Lymphocytic Leukemia (CLL) Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2032
Chronic Lymphocytic Leukemia (CLL) Market Report Overview The Chronic Lymphocytic Leukemia (CLL) market size for the seven major pharmaceutical markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan) was at $8.4 billion in 2022. The CLL market will register a CAGR of less than 1% from 2022 to 2032. The CLL market research report offers an overview of CLL, including epidemiology, symptoms, diagnosis, and disease management. The report offers key topics covered including strategic competitor assessment, market characterization, unmet...
-
Sector Analysis
Acute Myeloid Leukemia (AML) Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2032
Acute Myeloid Leukemia (AML) Market Report Overview The acute myeloid leukemia (AML) market in the eight major markets (8MM: the US, France, Germany, Italy, Spain, the UK, Japan, and China) was $2.3 billion in 2022. Steady growth is anticipated at a CAGR of more than 4% throughout the forecast period as the number of AML patients continues to climb and new therapies arrive in the 8MM. The AML market research report offers an overview of AML, including epidemiology, symptoms, diagnosis,...
-
Product Insights
Acute Myelocytic Leukemia Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Acute Myelocytic Leukemia Clinical Trials Market Report Overview A total of 4,834 Acute Myelocytic Leukemia clinical trials were conducted as of March 2023. The Acute Myelocytic Leukemia clinical trial report provides a comprehensive understanding of the Acute Myelocytic Leukemia clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor types and the prominent sponsors associated with the trials. Key...
-
Sector Analysis
Chronic Lymphocytic Leukemia (CLL) – Cell Therapies 15-Market Assessment and Sales Forecast to 2031
Chronic Lymphocytic Leukemia (CLL) – Cell Therapies 15-Market Report Overview The total market value for the 15MM, which includes both cell therapies and established/traditional CLL therapies was $13.2 billion in 2021. Allogeneic stem cell transplant is becoming less popular due to high levels of morbidity and CAR-T seems an attractive replacement to induce long-term disease control. Chronic Lymphocytic Leukemia (CLL) – Cell Therapies 15-Market Outlook, 2021-2031 ($ Billion) Buy the Full Report to Know More about Chronic Lymphocytic Leukemia (CLL)...
-
Sector Analysis
Acute Lymphocytic Leukemia (ALL) – Cell Therapies 15-Market Assessment and Sales Forecast to 2031
Acute Lymphocytic Leukemia (ALL) – Cell Therapies 15-Market Report Overview The total market value for the 15M, which includes both cell therapies and established/traditional ALL therapies was $2.3 billion in 2021. The need for “off-the-shelf” products with lower costs and reduced infrastructure requirements raises the development of allogeneic agents thereby driving the market growth. Acute Lymphocytic Leukemia (ALL) – Cell Therapies 15-Market Outlook, 2021-2031 ($ Billion) Buy the Full Report to Know More about the Acute Lymphocytic Leukemia (ALL) –...